This advise is mainly due to the absence of clinical parameters such as prostate specific antigen (PSA), digital rectal examination (DRE) or imaging technique able to identify which patients will have PCa on follow biopsy. The gene discussed is KLK3; the disease is posterior cortical atrophy.